Long non-coding RNA LOC389641 promotes progression of pancreatic ductal adenocarcinoma and increases cell invasion by regulating E-cadherin in a TNFRSF10A-related manner

Cancer Letters

Volumn 371, Issue 2, 2016, Pages 354-365

  Zheng, Shangyou ^a   Chen, Huimou ^a   Wang, Yingxue ^a   Gao, Wenchao ^a   Fu, Zhiqiang ^a   Zhou, Quanbo ^a   Jiang, Yanhui ^a   Lin, Qing ^a   Tan, Langping ^a   Ye, Huilin ^a   Zhao, Xiaohui ^a   Luo, Yuming ^a   Li, Guolin ^a   Ye, Liangtao ^a   Liu, Yimin ^a   Li, Wenzhu ^a   Li, Zhihua ^a   Chen, Rufu ^a  

^a SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

E cadherin; Invasion; LncRNAs; Pancreatic ductal adenocarcinoma; TNFRSF10A

Indexed keywords

LOC389641; LONG UNTRANSLATED RNA; UNCLASSIFIED DRUG; UVOMORULIN; CADHERIN; CDH1 PROTEIN, HUMAN; LOC389641 LONG NON-CODING RNA, HUMAN; TNFRSF10A PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ADULT; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN RNA BINDING; TNFRSF10A GENE; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; GENETIC TRANSFECTION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; NUDE MOUSE; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; APOPTOSIS; CADHERINS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA INTERFERENCE; RNA, LONG NONCODING; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION;

EID: 84962022977     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.12.010     Document Type: Article

References (45)

1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J. Clin 2015, 65:5-29.
2. Hidalgo M. Pancreatic cancer. N. Engl. J. Med 2010, 362:1605-1617.
3. Stathis A., Moore M.J. Advanced pancreatic carcinoma: current treatment and future challenges. Nat. Rev. Clin. Oncol 2010, 7:163-172.
4. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
5. Hong S.M., Park J.Y., Hruban R.H., Goggins M. Molecular signatures of pancreatic cancer. Arch. Pathol. Lab. Med 2011, 135:716-727.
6. Mohammed S., Van Buren G., Fisher W.E. Pancreatic cancer: advances in treatment. World J. Gastroenterol 2014, 20:9354-9360.
7. Mercer T.R., Mattick J.S. Structure and function of long noncoding RNAs in epigenetic regulation. Nat. Struct. Mol. Biol 2013, 20:300-307.
8. Wilusz J.E., Sunwoo H., Spector D.L. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev 2009, 23:1494-1504.
9. Hirata H., Hinoda Y., Shahryari V., Deng G., Nakajima K., Tabatabai Z.L., et al. Long noncoding RNA MALAT1 promotes aggressive renal cell carcinoma through Ezh2 and interacts with miR-205. Cancer Res 2015, 75:1322-1331.
10. Batista P.J., Chang H.Y. Long noncoding RNAs: cellular address codes in development and disease. Cell 2013, 152:1298-1307.
11. Huarte M., Rinn J.L. Large non-coding RNAs: missing links in cancer?. Hum. Mol. Genet 2010, 19:R152-R161.
12. Cheng Y., Jutooru I., Chadalapaka G., Corton J.C., Safe S. The long non-coding RNA HOTTIP enhances pancreatic cancer cell proliferation, survival and migration. Oncotarget 2015, 6:10840-10852.
13. Jiao F., Hu H., Han T., Yuan C., Wang L., Jin Z., et al. Long noncoding RNA MALAT-1 enhances stem cell-like phenotypes in pancreatic cancer cells. Int. J. Mol. Sci 2015, 16:6677-6693.
14. Kim K., Jutooru I., Chadalapaka G., Johnson G., Frank J., Burghardt R., et al. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene 2013, 32:1616-1625.
15. Li Z., Zhao X., Zhou Y., Liu Y., Zhou Q., Ye H., et al. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer. J. Transl. Med 2015, 13:84.
16. Ma C., Nong K., Zhu H., Wang W., Huang X., Yuan Z., et al. H19 promotes pancreatic cancer metastasis by derepressing let-7's suppression on its target HMGA2-mediated EMT. Tumour Biol 2014, 35:9163-9169.
17. Ye Y., Chen J., Zhou Y., Fu Z., Zhou Q., Wang Y., et al. High expression of AFAP1-AS1 is associated with poor survival and short-term recurrence in pancreatic ductal adenocarcinoma. J. Transl. Med 2015, 13:137.
18. Tahira A.C., Kubrusly M.S., Faria M.F., Dazzani B., Fonseca R.S., Maracaja-Coutinho V., et al. Long noncoding intronic RNAs are differentially expressed in primary and metastatic pancreatic cancer. Mol. Cancer 2011, 10:141.
19. Klymkowsky M.W., Savagner P. Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. Am. J. Pathol 2009, 174:1588-1593.
20. Vleminckx K., Vakaet L., Mareel M., Fiers W., van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991, 66:107-119.
21. Arakawa S., Takahashi A., Ashikawa K., Hosono N., Aoi T., Yasuda M., et al. Genome-wide association study identifies two susceptibility loci for exudative age-related macular degeneration in the Japanese population. Nat. Genet 2011, 43:1001-1004.
22. Nakata I., Yamashiro K., Akagi-Kurashige Y., Miyake M., Kumagai K., Tsujikawa A., et al. Association of genetic variants on 8p21 and 4q12 with age-related macular degeneration in Asian populations. Invest. Ophthalmol. Vis. Sci 2012, 53:6576-6581.
23. Sun Y., Li S., Li H., Yang F., Bai Y., Zhao M., et al. TNFRSF10A-LOC389641 rs13278062 but not REST-C4orf14-POLR2B-IGFBP7 rs1713985 was found associated with age-related macular degeneration in a Chinese population. Invest. Ophthalmol. Vis. Sci 2013, 54:8199-8203.
24. Jin K., Luo G., Xiao Z., Liu Z., Liu C., Ji S., et al. Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancer. Drug Des. Devel. Ther 2015, 9:1247-1255.
25. Liu J.H., Chen G., Dang Y.W., Li C.J., Luo D.Z. Expression and prognostic significance of lncRNA MALAT1 in pancreatic cancer tissues. Asian Pac. J. Cancer Prev 2014, 15:2971-2977.
26. Peng W., Gao W., Feng J. Long noncoding RNA HULC is a novel biomarker of poor prognosis in patients with pancreatic cancer. Med. Oncol 2014, 31:346.
27. Sun Y.W., Chen Y.F., Li J., Huo Y.M., Liu D.J., Hua R., et al. A novel long non-coding RNA ENST00000480739 suppresses tumour cell invasion by regulating OS-9 and HIF-1alpha in pancreatic ductal adenocarcinoma. Br. J. Cancer 2014, 111:2131-2141.
28. Li J., Liu D., Hua R., Zhang J., Liu W., Huo Y., et al. Long non-coding RNAs expressed in pancreatic ductal adenocarcinoma and lncRNA BC008363 an independent prognostic factor in PDAC. Pancreatology 2014, 14:385-390.
29. Cao H., Xu E., Liu H., Wan L., Lai M. Epithelial-mesenchymal transition in colorectal cancer metastasis: a system review. Pathol. Res. Pract 2015, 211:557-569.
30. Tseng J.C., Chen H.F., Wu K.J. A twist tale of cancer metastasis and tumor angiogenesis. Histol. Histopathol 2015, 11638.
31. Ying L., Chen Q., Wang Y., Zhou Z., Huang Y., Qiu F. Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition. Mol. Biosyst 2012, 8:2289-2294.
32. Luo M., Li Z., Wang W., Zeng Y., Liu Z., Qiu J. Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. Cancer Lett 2013, 333:213-221.
33. Beuran M., Negoi I., Paun S., Ion A.D., Bleotu C., Negoi R.I., et al. The epithelial to mesenchymal transition in pancreatic cancer: a systematic review. Pancreatology 2015, 15:217-225.
34. Wu Y., Liu H., Shi X., Yao Y., Yang W., Song Y. The long non-coding RNA HNF1A-AS1 regulates proliferation and metastasis in lung adenocarcinoma. Oncotarget 2015, 6:9160-9172.
35. Sun N.X., Ye C., Zhao Q., Zhang Q., Xu C., Wang S.B., et al. Long noncoding RNA-EBIC promotes tumor cell invasion by binding to EZH2 and repressing E-cadherin in cervical cancer. PLoS ONE 2014, 9:e100340.
36. Cho H.S., Kang J.G., Lee J.H., Lee J.J., Jeon S.K., Ko J.H., et al. Direct regulation of E-cadherin by targeted histone methylation of TALE-SET fusion protein in cancer cells. Oncotarget 2015, 6(27):23837-23844.
37. Mercer T.R., Dinger M.E., Mattick J.S. Long non-coding RNAs: insights into functions. Nat. Rev. Genet 2009, 10:155-159.
38. Hoogwater F.J., Nijkamp M.W., Smakman N., Steller E.J., Emmink B.L., Westendorp B.F., et al. Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. Gastroenterology 2010, 138:2357-2367.
39. von Karstedt S., Conti A., Nobis M., Montinaro A., Hartwig T., Lemke J., et al. Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis. Cancer Cell 2015, 27:561-573.
40. Seila A.C., Calabrese J.M., Levine S.S., Yeo G.W., Rahl P.B., Flynn R.A., et al. Divergent transcription from active promoters. Science 2008, 322:1849-1851.
41. Kurihara M., Shiraishi A., Satake H., Kimura A.P. A conserved noncoding sequence can function as a spermatocyte-specific enhancer and a bidirectional promoter for a ubiquitously expressed gene and a testis-specific long noncoding RNA. J. Mol. Biol 2014, 426:3069-3093.
42. Hou C.H., Lin F.L., Hou S.M., Liu J.F. Cyr61 promotes epithelial-mesenchymal transition and tumor metastasis of osteosarcoma by Raf-1/MEK/ERK/Elk-1/TWIST-1 signaling pathway. Mol. Cancer 2014, 13:236.
43. Fuchs C.S., Fakih M., Schwartzberg L., Cohn A.L., Yee L., Dreisbach L., et al. TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: a randomized phase 1b/2 trial. Cancer 2013, 119:4290-4298.
44. Geng C., Hou J., Zhao Y., Ke X., Wang Z., Qiu L., et al. A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma. Am. J. Hematol 2014, 89:1037-1042.
45. Trauzold A., Siegmund D., Schniewind B., Sipos B., Egberts J., Zorenkov D., et al. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 2006, 25:7434-7439.